Literature DB >> 17970079

Flash wave light strongly enhanced the cytocidal effect of photodynamic therapy with acridine orange on a mouse osteosarcoma cell line.

Haruhiko Satonaka1, Katsuyuki Kusuzaki, Takao Matsubara, Ken Shintani, Toru Wakabayashi, Tomoki Nakamura, Akihiko Matsumine, Atsumasa Uchida.   

Abstract

A photodynamic therapy technique with acridine orange (AO-PDT) was experimentally developed and applied clinically to musculoskeletal sarcoma patients to reduce the surgical margin and obtain good limb function. Furthermore, various modalities to enhance and strengthen the cytocidal effect of AO-PDT were investigated. A recent report revealed that the use of stronger unfiltered xenon light in AO-PDT enhanced the cytocidal efficacy of this treatment modality. Therefore, in this study, we investigated whether the use of a flash wave light (FWL) from a xenon lamp, as compared to that of the conventional continuous wave light (CWL), might enhance the cytocidal effect of AO-PDT, using the mouse osteosarcoma cell line, LM8. For an equal energy dose (79.6 joules/cm2), AO-PDT using FWL (10 minutes excitation) was found to exert a significantly stronger cytocidal effect than that using CWL (18 seconds excitation). For the same excitation time (10 minutes' excitation), the use of FWL (79.6 jouleslcm2) was associated with a significantly stronger cytocidal effect of AO-PDT than that of CWL (3,820 joules/cm2). These results reveal that the use of FWL entails the need for a lower excitation energy and shorter excitation time than that of CWL for the cytocidal effect of AO-PDT to be observed against the osteosarcoma cells. In addition, FWL also has the advantage of generating low heat and of having the ability to homogenously illuminate a wider area. We therefore concluded that FWL is more useful for AO-PDT than CWL in terms of saving on the excitation time and of obtaining good efficacy of destruction of the residual tumor in the treatment of musculoskeletal sarcomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970079

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  In vivo anti-tumor activity of photodynamic therapy with intravenous administration of acridine orange, followed by illumination with high-power flash wave light in a mouse osteosarcoma model.

Authors:  Haruhiko Satonaka; Katsuyuki Kusuzaki; Takao Matsubara; Ken Shintani; Tomoki Nakamura; Akihiko Matsumine; Takahiro Iino; Atsumasa Uchida
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

2.  Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors.

Authors:  Elisabetta Iessi; Mariantonia Logozzi; Luana Lugini; Tommaso Azzarito; Cristina Federici; Enrico Pierluigi Spugnini; Davide Mizzoni; Rossella Di Raimo; Daniela F Angelini; Luca Battistini; Serena Cecchetti; Stefano Fais
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 3.  Progress of Phototherapy Applications in the Treatment of Bone Cancer.

Authors:  Jiachen Sun; Fei Xing; Joy Braun; Frank Traub; Pol Maria Rommens; Zhou Xiang; Ulrike Ritz
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

4.  Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (Review).

Authors:  Xianghong Zhang; Tang Liu; Zhihong Li; Xiangsheng Zhang
Journal:  Oncol Lett       Date:  2014-07-09       Impact factor: 2.967

5.  Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model.

Authors:  Stefania Lenna; Chiara Bellotti; Serena Duchi; Elisa Martella; Marta Columbaro; Barbara Dozza; Marco Ballestri; Andrea Guerrini; Giovanna Sotgiu; Tommaso Frisoni; Luca Cevolani; Greta Varchi; Mauro Ferrari; Davide Maria Donati; Enrico Lucarelli
Journal:  J Exp Clin Cancer Res       Date:  2020-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.